Ann: FDA meeting on Rexlemestrocel-L, CLBP and Opioid Cessation, page-5

  1. 387 Posts.
    lightbulb Created with Sketch. 283
    This is a truly strange one! Can't see why they would convene said meeting ahead of trial completion unless there was an interest in an early approval, or at least a lot of pressure to identify treatments that might reduce opioid use. Maybe preparation for approval at the interim analysis. Looking forward to finding out more about that at the AGM.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.